A Single-centre, Open-label, Sequential, Cross-over Study to Examine the Safety, Tolerability and Pharmacokinetics of 3 Ascending Single Intravenous Doses, a Single 1000microg Oral Dose and a Single 1000microg Inhaled Dose of GSK573719 in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Umeclidinium (Primary) ; Umeclidinium (Primary) ; Umeclidinium (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 09 Jul 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2010 Trial location (England) added as reported by ClinicalTrials.gov.
- 26 Apr 2010 New trial record